Home

Has your essential thrombocythemia (ET)
therapy stopped working?

You may be eligible to join a Phase 3 clinical research study in the U.S. that evaluates the potential of a new, investigational ET therapy to reduce the number of platelets in the blood. About the TrialThis Phase 3 clinical trial will assess the long-term safety and efficacy of ropeginterferon alfa-2b (P1101)

See if your eligible for the study


What is Essential Thrombocythemia?


What is the P1101 ET study?


Who can participate in the study?


What is the study therapy?


What can study participants expect?


Where are the clinical sites in the US?



Where are the clinical study sites in the U.S. and Canada?
(Rollover locations to view contact information)














MD Anderson Cancer Center

Principal Investigator: Dr Srdan Verstovsek

Study Coordinator: Nichole Ard

Site Phone: 713-745-4657

Site Email: nard@mdanderson.org

University of Texas Health Science Center at San Antonio

Principal Investigator: Dr Ruben Mesa

Study Coordinator: Cynthia Kirk

Site Phone: 210-450-8508 (office)

Site Email: kirkc1@uthscsa.edu

Weill Medical College of Cornell University

Principal Investigator: Dr Ghaith Abu-Zeinah

Study Coordinator: Roland Babmatee

Site Phone: N/A

Site Email: rob4010@med.cornell.edu

Mount Sinai Medical Center

Principal Investigator: Dr John Mascarenhas

Study Coordinator: Mikaela Dougherty

Site Phone: N/A

Site Email: mikaela.dougherty@mssm.edu

Froedtert Hospital and the Medical College of Wisconsin

Principal Investigator: Dr Laura Michaelis

Study Coordinator: Deepa Pereira

Site Phone: N/A

Site Email: dpereira@mcw.edu

Washington University School of Medicine

Principal Investigator: Dr Stephen Oh

Study Coordinator: Nicole Gaudin

Site Phone: 314-747-7960

Site Email: nrgaudin@wustl.com

Mayo Clinic – Scottsdale

Principal Investigator: Dr Jeanne Palmer

Study Coordinator: Chris Reed Peace

Site Phone: 480-342-6068

Site Email: reedpease.christine@mayo.edu

University of Michigan

Principal Investigator: Dr Kristen Pettit

Study Coordinator: Stephen Tryban

Site Phone: 734-615-0052

Site Email: stephtho@med.umich.edu

University of Utah

Principal Investigator: Dr Tsewang Tashi

Study Coordinator: Karen Pena

Site Phone: 801-213-5601

Site Email: karen.pena@hci.utah.edu

University of Kansas Cancer Center

Principal Investigator: Dr Abdulraheem Yacoub


Study Coordinator: Marc Morrison

Site Phone: 913-588-7585

Site Email: mmorrison3@kumc.edu


MD Anderson Cancer Center

Principal Investigator: Srdan Verstovsek, MD

Study Coordinator: Nichole Ard

Site Phone:

Site Email: nard@mdanderson.org

Princess Margaret Cancer Centre

Principal Investigator: DawnMaze

Study Coordinator: Nicole Sokolsky

Site Phone: 416-946-4501 ext. 5834

Site Email: dawn.maze@uhn.ca.

St. Paul’s Hospital

Principal Investigator: Linda Foltz

Study Coordinator: Tathiana Ruiz

Site Phone: 604-682-2344 ext. 64987

Site Email: N/A

Jewish General Hospital

Principal Investigator: Shireen Sirhan

Study Coordinator: Chadi Zakaria

Site Phone: 514-340-8222 Ext 28326

Site Email: chadi.zakaria.ccomtl@ssss.gouv.qc.ca

What is Essential Thrombocythemia?

Essential Thrombocythemia

Essential thrombocythemia (ET) is a condition characterized by an excessive increase of the number of platelets in your blood. Platelets cause blot clots and vascular complications. Some people with ET have no symptoms, while others develop many health problems due to additional platelets in the blood.

Symptoms can include the following:

  • Weakness and fatigue
  • Burning, tingling, or prickling skin sensations
  • Excessive bleeding (like nosebleeds or bleeding gums)
  • Headaches
  • Pain, redness, and swelling of the hands and feet
  • An enlarged spleen

ET can also cause more serious problems from increased risk of blood clots, including strokes and heart attacks, although these are rare events.
Controlling the number of platelets in the blood can help to reduce these
symptoms and health risks.


The P1101 ET Study

The P1101 ET study is for people with ET, who have tried other therapy options, like hydroxyurea, that are no longer effective at controlling their ET or that have such extreme side effects that people stop using them. The goal of this study is to compare the new study therapy, ropeginterferon alfa-2b (P1101), to the approved ET therapy, anagrelide.

The study therapy (P1101) is considered investigational because it has not been approved for public use in ET and can only be used in clinical research studies like this P1101 ET study. The study therapy (P1101) is designed to reduce the number of platelets in the blood. It is given as an injection under the skin every 2 weeks.


Who can participate in the study?You may qualify to participate in the study if you meet basic study requirements*:

  • 18 years of age or older
  • Diagnosed with high-risk ET (defined as having disease-related blood clots or bleeding in the past and/or being over 60 years of age and JAK2 positive)
  • Received hydroxyurea for ET
  • Never received interferon therapy
  • *Other study requirements will apply.

What is the study therapy?PharmaEssentia

  • The study therapy (P1101) is a type of interferon designed to reduce the number of platelets in the blood


Study Overview—What To ExpectStudy participation will last about 14 months and is divided into 3 study periods:

Study Qualification

4 Weeks

You should have already completed the Study Qualification period to confirm that
you qualify for the study.

Study Participation

52 Weeks

  • You will be randomly assigned to receive either the study therapy (P1101) or the approved ET therapy (anagrelide). You will have an equal chance of receiving either therapy. You and your study doctor will know your therapy assignment.
  • You will come to the study center every 2 weeks. You will have study tests and procedures (like those during Study Qualification) to monitor your health during the study. If you are assigned the study therapy (P1101), you will receive an injection at each study visit. If you are assigned the approved ET therapy (anagrelide), you will take this daily at home and bring your bottle to each 2-week visit, so the study staff can make sure you are following instructions and find out if your dose needs to change.
  • In addition to the study therapy (P1101) or approved ET therapy (anagrelide), you will also take low-dose aspirin as prescribed by your doctor unless you are medically unable to take aspirin.

Study Follow-up

4 Weeks after last treatment visit

  • You will come to the study center for your last study visit to check your health status 28 days after you complete the Study Therapy period.
  • You will have study tests and procedures (like those during Study Therapy and Study Qualification) and will answer more questions about your health.

Post-Study Therapy

  • If you completed the study, and if your doctor determines it is the best option for you, you may have the opportunity to continue receiving study therapy (P1101), or start receiving it if you were receiving the ET therapy (anagrelide), until it becomes commercially available.



Where are the clinical study sites in the U.S. and Canada?
(Rollover locations to view contact information)











MD Anderson Cancer Center

Principal Investigator: Dr Srdan Verstovsek

Study Coordinator: Nichole Ard

Site Phone: 713-745-3429

Site Email: nard@mdanderson.org

University of Texas Health Science Center at San Antonio

Principal Investigator: Dr Ruben Mesa

Study Coordinator: Epp Goodwin

Site Phone: 210-450-5798

Site Email: goodwine@uthscsa.edu

Weill Medical College of Cornell University

Principal Investigator: Dr Ghaith Abu-Zeinah

Study Coordinator: Niamh Savage

Site Phone: 212-746-0284

Site Email: nis2049@med.cornell.edu

Mount Sinai Medical Center

Principal Investigator: Dr John Mascarenhas

Study Coordinator: Lonette Sandy

Site Phone: 212-241-4546

Site Email: lonette.sandy@mssm.edu

Froedtert Hospital and the Medical College of Wisconsin

Principal Investigator: Dr Laura Michaelis

Study Coordinator: Paulette Jacobs

Site Phone: 414-805-4196

Site Email: pjacobs@mcw.edu

Washington University School of Medicine

Principal Investigator: Dr Stephen Oh

Study Coordinator: Karyn Gordon

Site Phone: 314-362-0156

Site Email: kdgordon@wustl.edu

Mayo Clinic – Scottsdale

Principal Investigator: Dr Jeanne Palmer

Study Coordinator: Crystal Anderson

Site Phone: 855-776-0015

Site Email: anderson.crystal2@mayo.edu

University of Michigan

Principal Investigator: Dr Kristen Pettit

Study Coordinator: Stephen Tryban

Site Phone: 734-615-0052

Site Email: stephtho@med.umich.edu

University of Utah

Principal Investigator: Dr Tsewang Tashi

Study Coordinator: Karen Pena

Site Phone: 801-213-5601

Site Email: karen.pena@hci.utah.edu

University of Kansas Cancer Center

Principal Investigator: Dr Abdulraheem Yacoub


Study Coordinator: Marc Morrison

Site Phone: 913-588-7585

Site Email: mmorrison3@kumc.edu


MD Anderson Cancer Center

Principal Investigator: Srdan Verstovsek, MD

Study Coordinator: Nichole Ard

Site Phone:

Site Email: nard@mdanderson.org















MD Anderson Cancer Center

Principal Investigator: Dr Srdan Verstovsek

Study Coordinator: Nichole Ard

Site Phone: 713-745-4657

Site Email: nard@mdanderson.org

University of Texas Health Science Center at San Antonio

Principal Investigator: Dr Ruben Mesa

Study Coordinator: Cynthia Kirk

Site Phone: 210-450-8508 (office)

Site Email: kirkc1@uthscsa.edu

Weill Medical College of Cornell University

Principal Investigator: Dr Ghaith Abu-Zeinah

Study Coordinator: Roland Babmatee

Site Phone: N/A

Site Email: rob4010@med.cornell.edu

Mount Sinai Medical Center

Principal Investigator: Dr John Mascarenhas

Study Coordinator: Mikaela Dougherty

Site Phone: N/A

Site Email: mikaela.dougherty@mssm.edu

Froedtert Hospital and the Medical College of Wisconsin

Principal Investigator: Dr Laura Michaelis

Study Coordinator: Deepa Pereira

Site Phone: N/A

Site Email: dpereira@mcw.edu

Washington University School of Medicine

Principal Investigator: Dr Stephen Oh

Study Coordinator: Nicole Gaudin

Site Phone: 314-747-7960

Site Email: nrgaudin@wustl.com

Mayo Clinic – Scottsdale

Principal Investigator: Dr Jeanne Palmer

Study Coordinator: Chris Reed Peace

Site Phone: 480-342-6068

Site Email: reedpease.christine@mayo.edu

University of Michigan

Principal Investigator: Dr Kristen Pettit

Study Coordinator: Stephen Tryban

Site Phone: 734-615-0052

Site Email: stephtho@med.umich.edu

University of Utah

Principal Investigator: Dr Tsewang Tashi

Study Coordinator: Karen Pena

Site Phone: 801-213-5601

Site Email: karen.pena@hci.utah.edu

University of Kansas Cancer Center

Principal Investigator: Dr Abdulraheem Yacoub


Study Coordinator: Marc Morrison

Site Phone: 913-588-7585

Site Email: mmorrison3@kumc.edu


MD Anderson Cancer Center

Principal Investigator: Srdan Verstovsek, MD

Study Coordinator: Nichole Ard

Site Phone:

Site Email: nard@mdanderson.org

Princess Margaret Cancer Centre

Principal Investigator: DawnMaze

Study Coordinator: Nicole Sokolsky

Site Phone: 416-946-4501 ext. 5834

Site Email: dawn.maze@uhn.ca.

St. Paul’s Hospital

Principal Investigator: Linda Foltz

Study Coordinator: Tathiana Ruiz

Site Phone: 604-682-2344 ext. 64987

Site Email: N/A

Jewish General Hospital

Principal Investigator: Shireen Sirhan

Study Coordinator: Chadi Zakaria

Site Phone: 514-340-8222 Ext 28326

Site Email: chadi.zakaria.ccomtl@ssss.gouv.qc.ca


Questions?

For more information
contact our Medical Information team at medinfo@pharmaessentia-us.com

PharmaEssentia USA
35 Corporate Drive, Suite 325
Burlington, MA 01803

About PharmaEssentia

Locations
SURPASS_ET_Microsite_-vRESUBMISSION-30